HER2 in uterine serous carcinoma: Testing platforms and implications for targeted therapy.

Tenley Klc,Sharon Wu,Annelise Wilhite,Nathaniel L. Jones,Matthew A. Powell,Alexander Olawaiye,Fiona Simpkins,Eugenia Girda,Jubilee Brown,Allison Puechl,Rouba Ali-Fehmi,Ira Winer,Thomas J. Herzog,Wolfgang Michael Korn,Britt K. Erickson

HER2 in uterine serous carcinoma: Testing platforms and implications for targeted therapy.

2021

Tenley Klc
Sharon Wu
Annelise Wilhite
Nathaniel L. Jones
Matthew A. Powell
Alexander Olawaiye
Fiona Simpkins
Eugenia Girda
Jubilee Brown
Allison Puechl
Rouba Ali-Fehmi
Ira Winer
Thomas J. Herzog
Wolfgang Michael Korn
Britt K. Erickson

5580Background: HER2 is an emerging prognostic and therapeutic target in uterine serous carcinoma (USC). Testing algorithms and platforms in breast and gastric cancers are well studied and validate...

Keywords:

Targeted therapy
Uterine serous carcinoma
Oncology
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations